Log in

Relevant bibliographies by topics / Aminopyridín / Journal articles

To see the other types of publications on this topic, follow the link: Aminopyridín.

Journal articles on the topic 'Aminopyridín'

Author: Grafiati

Published: 4 June 2021

Last updated: 18 February 2022

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the top 50 journal articles for your research on the topic 'Aminopyridín.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Browse journal articles on a wide variety of disciplines and organise your bibliography correctly.

1

Prakash, Shet M., S. Naveen, N. K. Lokanath, P. A. Suchetan, and Ismail Warad. "Crystal structures of 2-aminopyridine citric acid salts: C5H7N2 +·C6H7O7 − and 3C5H7N2 +·C6H5O7 3−." Acta Crystallographica Section E Crystallographic Communications 74, no. 8 (2018): 1111–16. http://dx.doi.org/10.1107/s2056989018009787.

Full text

Abstract:

2-Aminopyridine and citric acid mixed in 1:1 and 3:1 ratios in ethanol yielded crystals of two 2-aminopyridinium citrate salts, viz. C5H7N2 +·C6H7O7 − (I) (systematic name: 2-aminopyridin-1-ium 3-carboxy-2-carboxymethyl-2-hydroxypropanoate), and 3C5H7N2 +·C6H5O7 3− (II) [systematic name: tris(2-aminopyridin-1-ium) 2-hydroxypropane-1,2,3-tricarboxylate]. The supramolecular synthons present are analysed and their effect upon the crystal packing is presented in the context of crystal engineering. Salt I is formed by the protonation of the pyridine N atom and deprotonation of the central carboxyli

APA, Harvard, Vancouver, ISO, and other styles

2

Gerhardt, Valeska, and Michael Bolte. "6-Chloroisocytosine and 5-bromo-6-methylisocytosine: again, one or two tautomers present in the same crystal?" Acta Crystallographica Section C Structural Chemistry 72, no. 1 (2016): 84–93. http://dx.doi.org/10.1107/s2053229615024080.

Full text

Abstract:

It is well known that pyrimidin-4-one derivatives are able to adopt either the 1H- or the 3H-tautomeric form in (co)crystals, depending on the coformer. As part of ongoing research to investigate the preferred hydrogen-bonding patterns of active pharmaceutical ingredients and their model systems, 2-amino-6-chloropyrimidin-4-one and 2-amino-5-bromo-6-methylpyrimidin-4-one have been cocrystallized with several coformers and with each other. Since Cl and Br atoms both have versatile possibilities to interact with the coformers, such asviahydrogen or halogen bonds, their behaviour within the cryst

APA, Harvard, Vancouver, ISO, and other styles

3

Husseini, L., V. I. Leussink, B. C. Kieseier, and H. P. Hartung. "4-Aminopyridin (Fampridin)." Der Nervenarzt 81, no. 2 (2010): 203–11. http://dx.doi.org/10.1007/s00115-009-2902-2.

Full text

APA, Harvard, Vancouver, ISO, and other styles

4

NISHIURA, Kazuo. "4-Aminopyridine." Journal of Synthetic Organic Chemistry, Japan 48, no. 7 (1990): 693–94. http://dx.doi.org/10.5059/yukigoseikyokaishi.48.693.

Full text

APA, Harvard, Vancouver, ISO, and other styles

5

&NA;. "Aminopyridine overdose." Reactions Weekly &NA;, no. 529 (1994): 4. http://dx.doi.org/10.2165/00128415-199405290-00008.

Full text

APA, Harvard, Vancouver, ISO, and other styles

6

Netto, A. Marques, S. M. C. M. Bicalho, Ca L. Filgueiras, and J. C. Machado. "Positron annihilation studies in solid 2-aminopyridine, 3-aminopyridine, 4-aminopyridine and 2-aminopyrimidine." Chemical Physics Letters 119, no. 6 (1985): 507–10. http://dx.doi.org/10.1016/0009-2614(85)85378-1.

Full text

APA, Harvard, Vancouver, ISO, and other styles

7

Betz, Richard, Thomas Gerber, Eric Hosten, and Henk Schalekamp. "2-Aminopyridin-3-ol." Acta Crystallographica Section E Structure Reports Online 67, no. 9 (2011): o2513. http://dx.doi.org/10.1107/s1600536811034775.

Full text

APA, Harvard, Vancouver, ISO, and other styles

8

Sauer, Elizabeta, Melisa Merdanovic, Anne Price Mortimer, Gerhard Bringmann, and Joachim Reidl. "PnuC and the Utilization of the Nicotinamide Riboside Analog 3-Aminopyridine in Haemophilus influenzae." Antimicrobial Agents and Chemotherapy 48, no. 12 (2004): 4532–41. http://dx.doi.org/10.1128/aac.48.12.4532-4541.2004.

Full text

Abstract:

ABSTRACT The utilization pathway for the uptake of NAD and nicotinamide riboside was previously characterized for Haemophilus influenzae. We now report on the cellular location, topology, and substrate specificity of PnuC. pnuC of H. influenzae is only distantly related to pnuC of Escherichia coli and Salmonella enterica serovar Typhimurium. When E. coli PnuC was expressed in an H. influenzae pnuC mutant, it was able to take up only nicotinamide riboside and not nicotinamide mononucleotide. Therefore, we postulated that PnuC transporters in general possess specificity for nicotinamide riboside

APA, Harvard, Vancouver, ISO, and other styles

9

Zhang, Liang, and Kresimir Krnjevic. "Effects of 4-aminopyridine on the action potential and the after-hyper polarization of cat spinal motoneurons." Canadian Journal of Physiology and Pharmacology 64, no. 11 (1986): 1402–6. http://dx.doi.org/10.1139/y86-237.

Full text

Abstract:

In cats under pentobarbital anaesthesia, intramotoneuronal administrations of 4-aminopyridine significantly prolong the falling phase of the antidromic action potential but have much less effect on the orthodromic action potential. 4-aminopyridine probably blocks the fast K channels involved in the repolarization of the membrane and indirectly activates ionic channels through enhancement of synaptic transmission, also suggested by the potentiation of excitatory postsynaptic potentials. In many cells, 4-aminopyridine depresses the amplitude and prolongs the time course of the after-hyperpolariz

APA, Harvard, Vancouver, ISO, and other styles

10

Klotz, Irving M., Solomon E. Massil, and Leigh E. Wood. "Poly(aminopyridine)s." Journal of Polymer Science: Polymer Chemistry Edition 23, no. 2 (1985): 575–79. http://dx.doi.org/10.1002/pol.1985.170230230.

Full text

APA, Harvard, Vancouver, ISO, and other styles

11

Akgul, Cahit, and Mehmet Yildirim. "Molecular weight dependent antistaphylococcal activities of oligomers/polymers synthesized from 3-aminopyridine." Journal of the Serbian Chemical Society 75, no. 9 (2010): 1203–8. http://dx.doi.org/10.2298/jsc100201104a.

Full text

Abstract:

The main aim of this study was to investigate the relationship between molecular weight and the antistaphylococcal activity of oligomers/polymers synthesized from 3-aminopyridine. Different oligomers/polymers were synthesized from 3-aminopyridine by changing the oxidative polycondensation reaction conditions. They were characterized by size exclusion chromatography and their antibacterial activities were compared by employing standardized susceptibility assays. The obtained experimental results demonstrated that 3-aminopyridine had no antistaphylococcal activity. However, as a result of polyme

APA, Harvard, Vancouver, ISO, and other styles

12

Reiss, Guido J., and Peer B. Leske. "2-Aminopyridin-1-ium triiodide." Acta Crystallographica Section E Structure Reports Online 69, no. 7 (2013): o1060—o1061. http://dx.doi.org/10.1107/s1600536813015389.

Full text

APA, Harvard, Vancouver, ISO, and other styles

13

Kostadinova, Ivanka, and Nikolai Danchev. "4-aminopyridine – the new old drug for the treatment of neurodegenerative diseases." Pharmacia 66, no. 2 (2019): 67–74. http://dx.doi.org/10.3897/pharmacia.66.e35976.

Full text

Abstract:

In this review are described the preclinical and clinical pharmacological data as well as new therapeutic indications for the use of 4-aminopyridine. 4-aminopyridine is a potassium (K+) channel blocker that has a long history and various application areas. It is a chemical agent developed in 1963 as a bird poison. The first approval for clinical application of 4-aminopyridine was in 70’s in Bulgaria, since anesthetists in that country have confirmed its effect as reversal agent for nondepolarizing myorelaxants. The Bulgarian pharmaceutical company Sopharma commersialized 4-aminopyridine under

APA, Harvard, Vancouver, ISO, and other styles

14

Kochel, Andrzej. "Tetrakis(3-aminopyridine-κN1)dioxorhenium(V) iodide 3-aminopyridine solvate dihydrate". Acta Crystallographica Section E Structure Reports Online 62, № 8 (2006): m1740—m1742. http://dx.doi.org/10.1107/s1600536806024603.

Full text

APA, Harvard, Vancouver, ISO, and other styles

15

Feil, K., N. Böttcher, O. Kremmyda, et al. "Medikamentöse Therapiemöglichkeiten bei vestibulären Störungen, Nystagmus und zerebellären Ataxien." Laryngo-Rhino-Otologie 97, no. 01 (2018): 14–23. http://dx.doi.org/10.1055/s-0043-123487.

Full text

Abstract:

ZusammenfassungZur Pharmakotherapie von vestibulären Erkrankungen kommen im Wesentlichen folgende Wirkstoffgruppen zum Einsatz: Antivertiginosa, Antikonvulsiva, Antidepressiva, Antiphlogistika, Anti-Menière-wirksame Substanzen, Migräneprophylaktika, Aminopyridine (Kaliumkanalblocker) und Acetyl-DL-Leucin (eine modifizierte essenzielle Aminosäure). Die Behandlung des Symptoms Schwindel und der begleitenden vegetativen Beschwerden wie Übelkeit, Brechreiz oder Erbrechen sollte zeitlich stets begrenzt werden. Bei einem akuten einseitigen Vestibularisausfall verbessern Kortikosteroide die Erholung

APA, Harvard, Vancouver, ISO, and other styles

16

Campos-Gaxiola, Jose J., Simón Hernández-Ortega, David Morales-Morales, and Adriana Cruz Enríquez. "3-Aminopyridin-1-ium 3-carboxybenzoate." Acta Crystallographica Section E Structure Reports Online 68, no. 5 (2012): o1444. http://dx.doi.org/10.1107/s1600536812016108.

Full text

APA, Harvard, Vancouver, ISO, and other styles

17

Sabino, J. R., C. H. T. P. da Silva, and M. Yonashiro. "6-Aminopyridine-3-thiol." Acta Crystallographica Section C Crystal Structure Communications 58, no. 2 (2002): o78—o79. http://dx.doi.org/10.1107/s0108270101020352.

Full text

APA, Harvard, Vancouver, ISO, and other styles

18

Saint, David A. "The effects of 4-aminopyridine and tetraethylammonium on the kinetics of transmitter release at the mammalian neuromuscular synapse." Canadian Journal of Physiology and Pharmacology 67, no. 9 (1989): 1045–50. http://dx.doi.org/10.1139/y89-165.

Full text

Abstract:

The effect of 4-aminopyridine and tetraethylammonium on the time course of neurotransmitter release was examined at the neuromuscular junction using a computer-aided method which directly measured the time of occurrence of individual quanta. It is apparent that the action of 4-aminopyridine, at concentrations of 0.1 to 1 mM, when examined in isolation from other experimental manipulations, is to cause a greatly enhanced probability of release at times subsequent to the time over which release normally occurs. In contrast to previous reports of an increased latency of release, however, the prob

APA, Harvard, Vancouver, ISO, and other styles

19

Glavinović, M. I. "Differences in presynaptic action of 4-aminopyridine and tetraethylammonium at frog neuromuscular junction." Canadian Journal of Physiology and Pharmacology 65, no. 5 (1987): 747–52. http://dx.doi.org/10.1139/y87-121.

Full text

Abstract:

4-Aminopyridine markedly potentiates transmitter release at the frog cutaneous pectoris neuromuscular junction by increasing the quantal content even when applied at low concentrations (5–20 μM). This enhancement of transmitter release is associated with greater minimum synaptic latency, but the dispersion of the synaptic latencies does not appear much affected. This is in contrast with the action of tetraethylammonium (0.2–0.5 mM) in which case similar enhancement of transmitter release results not only in larger minimum synaptic latency but also in greater dispersion of the synaptic latencie

APA, Harvard, Vancouver, ISO, and other styles

20

Shatsauskas, Anton L., Anton A. Abramov, Sergey A. Chernenko, Anastasia S. Kostyuchenko та Alexander S. Fisyuk. "Synthesis and Photophysical Properties of 3-Amino-4-arylpyridin-2(1Н)-ones". Synthesis 52, № 02 (2019): 227–38. http://dx.doi.org/10.1055/s-0039-1690231.

Full text

Abstract:

A method has been developed for the preparation of oxazolo-[5,4-b]pyridin-2(1H)-ones based on the Hoffmann reaction of 2-oxo-1,2-dihydropyridine-3-carboxamides. Hydrolysis of oxazolo[5,4-b]pyridin-2(1H)-ones and the Hoffmann reaction of 2-oxo-1,2-dihydropyridine-3-carboxamides yielded 3-aminopyridin-2(1H)-ones, including 4-aryl substituted derivatives in the series, for which effective phosphors with a quantum yield of up to 0.78 were detected. Photophysical properties of 3-aminopyridin-2(1H)-ones were studied by UV and luminescence spectroscopy methods, and the relationship between their stru

APA, Harvard, Vancouver, ISO, and other styles

21

Iriepa, I., A. Lorente, E. Galvez, P. Rubio, F. Florencio, and S. Garcia-Blanco. "Synthesis and spectroscopic study of aminals derived from 2-aminopyridine and 3-aminopyridine." Journal of Molecular Structure 142 (March 1986): 443–46. http://dx.doi.org/10.1016/0022-2860(86)85152-3.

Full text

APA, Harvard, Vancouver, ISO, and other styles

22

Schniepp, Roman, Veronika Jakl, Max Wuehr, et al. "Treatment with 4-aminopyridine improves upper limb tremor of a patient with multiple sclerosis: a video case report." Multiple Sclerosis Journal 19, no. 4 (2012): 506–8. http://dx.doi.org/10.1177/1352458512461394.

Full text

Abstract:

The reversible potassium channel blocker 4-aminopyridine is effective in the treatment of numerous cerebellar dysfunctions, such as episodic ataxia type 2 and downbeat nystagmus syndrome. In 2011, its sustained release form, dalfampridine, was admitted in Europe for the treatment of walking difficulties in patients with multiple sclerosis (MS). Here we report the case of a 44-year old patient with a progressive MS whose upper limb tremor was markedly reduced under treatment with 4-aminopyridine, as documented in a Tremor Activities of Daily Living questionnaire and in the 9-Hole Peg test. Hand

APA, Harvard, Vancouver, ISO, and other styles

23

Ruiz-Petrich, Elena, and Normand Leblanc. "The mechanism of the rate-dependent changes of the conducted action potential in rabbit ventricle." Canadian Journal of Physiology and Pharmacology 67, no. 7 (1989): 780–87. http://dx.doi.org/10.1139/y89-124.

Full text

Abstract:

Blockers of the transient outward current (4-aminopyridine) and the Ca current (Co2+) as well as injection of polarizing current during the plateau were used to assess the role of these current systems as determinants of action potential duration at different pacing rates. Papillary muscles and ventricular trabecula were superfused with oxygenated Krebs solution at 33 °C and driven at a basic rate of 1 Hz. The effects of varying the frequency of stimulation between 0.1 and 4 Hz on action potential parameters were determined under control conditions and during exposure to 2 mM 4-aminopyridine,

APA, Harvard, Vancouver, ISO, and other styles

24

Seethalakshmi, T., P. Venkatesan, M. Nallu, Daniel E. Lynch, and S. Thamotharan. "1-Allyl-2-aminopyridin-1-ium bromide." Acta Crystallographica Section E Structure Reports Online 69, no. 6 (2013): o884. http://dx.doi.org/10.1107/s1600536813012452.

Full text

APA, Harvard, Vancouver, ISO, and other styles

25

Fields, Stephen C., William C. Lo, William K. Brewster, and Christian T. Lowe. "Electrophilic fluorination: the aminopyridine dilemma." Tetrahedron Letters 51, no. 1 (2010): 79–81. http://dx.doi.org/10.1016/j.tetlet.2009.10.089.

Full text

APA, Harvard, Vancouver, ISO, and other styles

26

Kukharev, B. F., V. K. Stankevich, G. R. Klimenko, and V. A. Kukhareva. "2-Aminopyridine condensation with formaldehyde." Russian Journal of Organic Chemistry 45, no. 8 (2009): 1255–56. http://dx.doi.org/10.1134/s1070428009080260.

Full text

APA, Harvard, Vancouver, ISO, and other styles

27

Yunnikova, L. P., Yu E. Likhareva, and T. A. Akent’eva. "Electrophilic tropylation of 2-aminopyridine." Russian Journal of General Chemistry 87, no. 2 (2017): 347–49. http://dx.doi.org/10.1134/s1070363217020323.

Full text

APA, Harvard, Vancouver, ISO, and other styles

28

&NA;. "4-Aminopyridine encouraging in MS." Inpharma Weekly &NA;, no. 854 (1992): 18. http://dx.doi.org/10.2165/00128413-199208540-00039.

Full text

APA, Harvard, Vancouver, ISO, and other styles

29

Polman, C. H., H. A. M. van Diemen, M. M. M. M. van Dongen, J. C. Koetsier, A. C. van Loenen, and H. K. van Walbeek. "4-Aminopyridine in multiple sclerosis." Annals of Neurology 28, no. 4 (1990): 589. http://dx.doi.org/10.1002/ana.410280421.

Full text

APA, Harvard, Vancouver, ISO, and other styles

30

Xie, Zhi-Yuan. "2-Aminopyridinium isonicotinate 2-aminopyridine." Acta Crystallographica Section E Structure Reports Online 63, no. 5 (2007): o2192—o2193. http://dx.doi.org/10.1107/s160053680701344x.

Full text

APA, Harvard, Vancouver, ISO, and other styles

31

Ju, Wen-Zheng, Rui-Hua Jiao, Ping Cao, and Rui-Qin Fang. "Bis(2-aminopyridine)dibenzoatocobalt(II)." Acta Crystallographica Section E Structure Reports Online 62, no. 5 (2006): m1012—m1013. http://dx.doi.org/10.1107/s1600536806011925.

Full text

Abstract:

The title compound, [Co(C7H5O2)2(C5H6N2)2], contains CoII cations bonded to two bidentate benzoate ligands and two 2-aminopyridine ligands, resulting in highly distorted cis-CoN2O4 octahedra. The crystal structure is stabilized by N—H...O hydrogen bonds.

APA, Harvard, Vancouver, ISO, and other styles

32

van Diemen, H. A. M., M. M. M. M. van Dongen, A. C. van Loenen, J. C. Koetsier, C. H. Polman, and H. K. van Walbeek. "Multiple Sclerosis and 4-Aminopyridine." Clinical Neurology and Neurosurgery 93, no. 4 (1991): 356. http://dx.doi.org/10.1016/0303-8467(91)90124-8.

Full text

APA, Harvard, Vancouver, ISO, and other styles

33

Dietrich, Michael, Hans-Peter Hartung, and Philipp Albrecht. "Neuroprotective Properties of 4-Aminopyridine." Neurology - Neuroimmunology Neuroinflammation 8, no. 3 (2021): e976. http://dx.doi.org/10.1212/nxi.0000000000000976.

Full text

Abstract:

As an antagonist of voltage-gated potassium (Kv) channels, 4-aminopyridine (4-AP) is used as symptomatic therapy in several neurologic disorders. The improvement of visual function and motor skills and relieve of fatigue in patients with MS have been attributed to 4-AP. Its prolonged release formulation (fampridine) has been approved for the symptomatic treatment of walking disability in MS. The beneficial effects were explained by the blockade of axonal Kv channels, thereby enhancing conduction along demyelinated axons. However, an increasing body of evidence suggests that 4-AP may have addit

APA, Harvard, Vancouver, ISO, and other styles

34

Boyd, A. S. F., M. J. Frost, and N. M. Howarth. "Experimental and ab initio computational studies of self-association: 2-aminopyridine and 3-aminopyridine." Journal of Molecular Structure 688, no. 1-3 (2004): 149–58. http://dx.doi.org/10.1016/j.molstruc.2003.10.006.

Full text

APA, Harvard, Vancouver, ISO, and other styles

35

Wu, Jing, Han Xing Liu, Zhi Dong Lin, et al. "Electroactive Organic-Inorganic Layered Perovskite Hybrids: Steric Interaction between Aminopyridine and Trivalent Ferricyanide and Use for Electrochemical Sensing Device." Materials Science Forum 682 (March 2011): 239–49. http://dx.doi.org/10.4028/www.scientific.net/msf.682.239.

Full text

Abstract:

Steady organic-inorganic perovskite hybrids with (H22-Ap)3/2Fe(CN)6, (H23-Ap)3/2Fe(CN)6 and (H24-AP)3/2Fe(CN)6 (2-AP = 2-aminopyridine, 3-AP = 3- aminopyridine, 4-AP = 4- aminopyridine) were formed from aqueous solution. Each structure was an unusual layered organic-inorganic structural type. A device was designed to construct electrochemical sensing devices using above organic-inorganic perovskite hybrids. The sequence of redox activity is (H24-Ap)3/2Fe(CN)6 > (H22-Ap)3/2Fe(CN)6 > (H23-AP)3/2Fe(CN)6 and that of electrocatalytical activity is (H22-Ap)3/2Fe(CN)6 > (H23-Ap)3/2Fe(CN)6 &g

APA, Harvard, Vancouver, ISO, and other styles

36

Hill, Ceredwyn E., та David O. Ajikobi. "Inhibition of α-adrenergic responses in the rat liver by lipophilic K+ channel blockers or depolarizing Cl− gradients. Evidence for a potential-sensitive step in the signal transduction path". Biochemistry and Cell Biology 71, № 5-6 (1993): 229–35. http://dx.doi.org/10.1139/o93-035.

Full text

Abstract:

To study the role of K+ channels and membrane potential in α-adrenergic responses of the rat liver, lipophilic K+ channel blockers quinidine and 4-aminopyridine were used or external Cl− was replaced with gluconate, an impermeant ion. Glucose release, O2 uptake, portal pressure, and K+ flux were measured in the isolated perfused liver. The α-agonist phenylephrine caused biphasic changes in each parameter, a fast transient followed by sustained elevated responses. Infusion of 5 mM 4-aminopyridine, 0.1 mM quinidine, or gluconate prior to phenylephrine inhibited each parameter, with the greatest

APA, Harvard, Vancouver, ISO, and other styles

37

Fueta, Yukiko, and Massimo Avoli. "Pattern-and age-dependency of the antiepileptic effects induced by valproic acid in the rat hippocampus." Canadian Journal of Physiology and Pharmacology 69, no. 9 (1991): 1301–4. http://dx.doi.org/10.1139/y91-191.

Full text

Abstract:

The effects induced by the antiepileptic drug valproic acid were studied in the CA3 subfield of in vitro hippocampal slices obtained from young (16- to 27-day-old) and adult (over 60-day-old) rats. Spontaneous epileptiform discharges were induced by the addition of the convulsant 4-aminopyridine to the medium. Valproic acid (0.5 mM) selectively blocked the ictal epileptiform discharges in slices obtained from young rats. Interictal epileptiform discharges disappeared during perfusion with higher doses of valproic acid (2 mM). This blockade of interictal epileptiform activity was not observed w

APA, Harvard, Vancouver, ISO, and other styles

38

Krushkov, H., P. Shotekov, K. Krampfl, and A. Kossev. "4-Aminopyridin-Therapie bei Patienten mit multipler Sklerose." Klinische Neurophysiologie 37, no. 2 (2006): 133–37. http://dx.doi.org/10.1055/s-2006-940005.

Full text

APA, Harvard, Vancouver, ISO, and other styles

39

Schlame, Michael, and Hugh C. Jr Hemmings. "Inhibition by Volatile Anesthetics of Endogenous Glutamate Release from Synaptosomes by a Presynaptic Mechanism." Anesthesiology 82, no. 6 (1995): 1406–16. http://dx.doi.org/10.1097/00000542-199506000-00012.

Full text

Abstract:

Background Synaptic transmission is more sensitive than axonal conduction to the effects of general anesthetics. Previous studies of the synaptic effects of general anesthetics have focused on postsynaptic sites of action. We now provide direct biochemical evidence for a presynaptic effect of volatile anesthetics on neurotransmitter release. Methods Rat cerebrocortical synaptosomes (isolated presynaptic nerve terminals) were used to determine the effects of general anesthetics on the release of endogenous L-glutamate, the major fast excitatory neurotransmitter. Basal and evoked (by 4-aminopyri

APA, Harvard, Vancouver, ISO, and other styles

40

Zhu, Hai-Liang, Si-Chang Shao, Ji-Long Ma, Xiao-Yang Qiu, Lin Sun, and Song Yang. "Dibenzoato-di(2-aminopyridine)nickel(II)." Acta Crystallographica Section E Structure Reports Online 59, no. 10 (2003): m843—m844. http://dx.doi.org/10.1107/s1600536803019329.

Full text

APA, Harvard, Vancouver, ISO, and other styles

41

Stork, Christine M., and Robert S. Hoffman. "Characterization of 4-Aminopyridine in Overdose." Journal of Toxicology: Clinical Toxicology 32, no. 5 (1994): 583–87. http://dx.doi.org/10.3109/15563659409011063.

Full text

APA, Harvard, Vancouver, ISO, and other styles

42

Slézia, A., A. K. Kékesi, T. Szikra, et al. "Uridine release during aminopyridine-induced epilepsy." Neurobiology of Disease 16, no. 3 (2004): 490–99. http://dx.doi.org/10.1016/j.nbd.2004.02.011.

Full text

APA, Harvard, Vancouver, ISO, and other styles

43

Pickett, Tracy A., and Robert Enns. "Atypical Presentation of 4-Aminopyridine Overdose." Annals of Emergency Medicine 27, no. 3 (1996): 382–85. http://dx.doi.org/10.1016/s0196-0644(96)70277-9.

Full text

APA, Harvard, Vancouver, ISO, and other styles

44

Zhu, Hai-Liang, Qing-Fu Zeng, Dong-Sheng Xia, Xiu-Ying Liu, and Da-Qi Wang. "Bis(4-aminopyridine)silver(I) trifluoroacetate." Acta Crystallographica Section E Structure Reports Online 59, no. 9 (2003): m726—m728. http://dx.doi.org/10.1107/s1600536803017422.

Full text

APA, Harvard, Vancouver, ISO, and other styles

45

Ju, Wen-Zheng, Rui-Hua Jiao, Ping Cao, and Rui-Qin Fang. "Bis(2-aminopyridine)dibenzoatocobalt(II). Erratum." Acta Crystallographica Section E Crystallographic Communications 72, no. 11 (2016): 1675. http://dx.doi.org/10.1107/s2056989016015504.

Full text

APA, Harvard, Vancouver, ISO, and other styles

46

Bever, Christopher T. "4-Aminopyridine: Use in Multiple Sclerosis." CNS Drug Reviews 1, no. 2 (1995): 261–79. http://dx.doi.org/10.1111/j.1527-3458.1995.tb00286.x.

Full text

APA, Harvard, Vancouver, ISO, and other styles

47

He, Xiang, Can-Zhong Lu, Ya-Qin Yu, Shu-Mei Chen, Xiao-Yuan Wu, and Jiu-Hui Liu. "trans-Tetrakis(3-aminopyridine)dichlorocadmium(II)." Acta Crystallographica Section E Structure Reports Online 60, no. 11 (2004): m1639—m1640. http://dx.doi.org/10.1107/s1600536804025450.

Full text

APA, Harvard, Vancouver, ISO, and other styles

48

Qian, Hui-Fen, and Wei Huang. "4-Aminopyridinium azide 4-aminopyridine solvate." Acta Crystallographica Section E Structure Reports Online 66, no. 12 (2010): o3086. http://dx.doi.org/10.1107/s1600536810044843.

Full text

APA, Harvard, Vancouver, ISO, and other styles

49

Andreani, A. "4-Aminopyridine derivatives with antiamnesic activity." European Journal of Medicinal Chemistry 35, no. 1 (2000): 77–82. http://dx.doi.org/10.1016/s0223-5234(00)00103-3.

Full text

APA, Harvard, Vancouver, ISO, and other styles

50

Lenoir, H. H. C., and C. C. M. Janssen. "Synthesis of 14C-labelled 2-aminopyridine." Journal of Labelled Compounds and Radiopharmaceuticals 24, no. 2 (1987): 119–23. http://dx.doi.org/10.1002/jlcr.2580240202.

Full text

APA, Harvard, Vancouver, ISO, and other styles

We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!